# Rodin Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rodin-therapeutics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.rodintherapeutics.com
- Total disclosed funding: $40M
- Latest round: Series C (Sep 18, 2017)
- Investors on record: 6

## About

Based in Massachusetts, US, and founded in 2013, Rodin Therapeutics Inc. operates as a biopharmaceutical company that develops epigenetic drugs for neurological diseases. In November 2019, Alkermes acquired Rodin Therapeutics Inc. for USD 100 million upon completion and a further USD 850 million in milestone payments.

The company’s focus lies on synaptopathies, a group of disorders characterized by impaired communication between nerve cells in the brain, such as Neurodegenerative, Neuropsychiatric, and Neurodevelopmental diseases. Their approach involves designing molecules that target specific protein complexes to activate genes crucial for learning and memory safely. This, in theory, could enhance synaptic integrity and improve neurological function. Rodin Therapeutics is particularly interested in diseases like Alzheimer's, Parkinson's, and schizophrenia, all of which involve synaptic dysfunction.

## Funding rounds

- Series C, Sep 18, 2017, $27M — Atlas Venture, Hatteras Venture Partners, Third Point, GV, Remeditex Ventures
- Series A, May 23, 2014, $13M — Atlas Venture, Johnson & Johnson Innovation
- Seed, Jun 27, 2013 — Atlas Venture, Johnson & Johnson Innovation

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Seed, Series A, Series C
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Seed, Series A
- Hatteras Venture Partners (https://capitalatlas.ai/funds/hatteras-venture-partners) — Series C
- Third Point (https://capitalatlas.ai/funds/third-point) — Series C
- GV (https://capitalatlas.ai/funds/gv) — Series C
- Remeditex Ventures (https://capitalatlas.ai/funds/remeditex-ventures) — Series C